CSF Levels of Heart Fatty Acid Binding Protein are Altered During Early Phases of Alzheimer's Disease

2011 ◽  
Vol 22 (4) ◽  
pp. 1281-1288 ◽  
Author(s):  
Davide Chiasserini ◽  
Lucilla Parnetti ◽  
Ulf Andreasson ◽  
Henrik Zetterberg ◽  
David Giannandrea ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Fatty Acid ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Fatty Acid Binding ◽  
Acid Binding Protein ◽  
Csf Levels ◽  
Early Phases

CSF levels of heart fatty acid binding protein in Parkinson's and Alzheimer's disease

2016 ◽  
Vol 22 ◽  
pp. e33 ◽  
Author(s):  
Davide Chiasserini ◽  
Leonardo Biscetti ◽  
Paolo Eusebi ◽  
Lucia Farotti ◽  
Nicola Tambasco ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Fatty Acid ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Fatty Acid Binding ◽  
Acid Binding Protein ◽  
Csf Levels

scholarly journals P4-002: Cerebrospinal heart fatty-acid-binding protein as a biomarker for Alzheimer's disease

2013 ◽  
Vol 9 ◽  
pp. P705-P705
Author(s):  
Carlos Cruchaga ◽  
Oscar Harari ◽  
John Kauwe ◽  
Kelly Bales ◽  
Eve H. Pickering ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Fatty Acid ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Fatty Acid Binding ◽  
Acid Binding Protein

scholarly journals Cerebrospinal fluid heart fatty acid‐binding protein as a predictive biomarker of neurodegeneration in Alzheimer’s disease

2021 ◽  
Vol 7 (1) ◽  
pp. 44-55
Author(s):  
Lu Pan ◽  
Ya-Nan Ou ◽  
Lin Tan ◽  
Lan Tan ◽  
Jin-Tai Yu
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Fatty Acid ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Predictive Biomarker ◽  
Fatty Acid Binding ◽  
Acid Binding Protein ◽  
T Tau

Objective This study aims to investigate whether the heart fatty acid‐binding protein (HFABP) in the cerebrospinal fluid (CSF) was a potential predictive biomarker for Alzheimer’s disease (AD). Methods We evaluated the associations of CSF HFABP levels with core biomarkers, cognition, and brain structure in a sample population ( n = 302) from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. Multiple linear regression and mixed‐effects models were employed in the analyses. AD progression was assessed using the Kaplan–Meier survival analysis. Results CSF HFABP was higher in patients with mild cognitive impairment and AD than the normal controls ( p < 0.001) and was particularly higher in those with amyloid‐β (Aβ) pathologic features. CSF HFABP was associated with higher baseline CSF t‐tau ( p < 0.001), CSF p‐tau ( p < 0.001), and CSF t‐tau/Aβ42 and CSF p‐tau/Aβ42 ( p < 0.01). Moreover, CSF HFABP was found to play predictive roles in hippocampal atrophy ( p < 0.01), cognitive decline ( p < 0.05), and the risk of AD ( p < 0.001). Conclusion Our findings suggest that CSF HFABP can be a predictive biomarker of AD.

Sign in / Sign up

Export Citation Format

Share Document